Prothena Corporation PLC (PRTA) Receiving Somewhat Favorable News Coverage, Report Shows

News stories about Prothena Corporation PLC (NASDAQ:PRTA) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prothena Corporation PLC earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.6575612797868 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Prothena Corporation PLC (NASDAQ PRTA) opened at 61.80 on Wednesday. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $70.00. The company has a 50-day moving average price of $62.13 and a 200 day moving average price of $57.47. The stock’s market cap is $2.37 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.43. The company had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. Prothena Corporation PLC’s quarterly revenue was up 7951.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.18) EPS. On average, analysts expect that Prothena Corporation PLC will post ($4.41) earnings per share for the current year.

A number of research analysts have recently weighed in on the company. ValuEngine lowered Prothena Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Deutsche Bank AG restated a “buy” rating on shares of Prothena Corporation PLC in a research report on Sunday, October 1st. Jefferies Group LLC restated a “buy” rating and set a $100.00 price objective on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. SunTrust Banks, Inc. restated a “buy” rating and set a $75.00 price objective on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. Finally, Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corporation PLC in a research report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $78.58.

TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/11/prothena-corporation-plc-prta-receiving-somewhat-favorable-news-coverage-report-shows.html.

In other Prothena Corporation PLC news, insider Tara Nickerson sold 17,500 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the sale, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher S. Henney sold 900 shares of the stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $70.00, for a total transaction of $63,000.00. Following the completion of the sale, the director now owns 900 shares of the company’s stock, valued at approximately $63,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,424 shares of company stock valued at $2,247,237. 3.10% of the stock is owned by insiders.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Insider Buying and Selling by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply